Sanara MedTech's sales grew in the third quarter of 2026, but it also reported a loss and updated its yearly forecast.

Nov 12, 2026, 5:35 PM ETResultsRead the original at manilatimes.net

Bad for SMTI

Sanara MedTech's third-quarter sales rose, and it kept 93 cents of each sales dollar after direct costs. But it cut its full-year sales forecast and moved from a year-earlier profit to a loss, making the update unfavorable.

SMTI · Sanara MedTech Inc.

AI read · Bad for SMTI

The AI's read

The lower forecast points to less sales than the company previously expected. Sales growth and keeping 93 cents of each sales dollar after direct costs are positives, but the forecast cut and swing to a loss weigh more. About $3.0 million in merger legal and advisory costs lowered operating income.

Get alerts for SMTI

Follow Sanara MedTech Inc. (SMTI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SMTI

Free on the App Store and Google Play, or on the web.